drugset / Trial / NCT05312268

Rasburicase Treatment in Chronic Gouty Arthritis

NCT05312268

RandomizedCrossoverOpen-labelTreatment

Summary

The study will establish efficacy and safety of rasburicase in chronic gouty arthritis

Timeline

Start
2022-06-15
Primary completion
2024-10-15
Completion
2025-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasburicase Protein / enzyme biologic 1.5 mg

Indications